CO5690608A2 - 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica - Google Patents
4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronicaInfo
- Publication number
- CO5690608A2 CO5690608A2 CO06051033A CO06051033A CO5690608A2 CO 5690608 A2 CO5690608 A2 CO 5690608A2 CO 06051033 A CO06051033 A CO 06051033A CO 06051033 A CO06051033 A CO 06051033A CO 5690608 A2 CO5690608 A2 CO 5690608A2
- Authority
- CO
- Colombia
- Prior art keywords
- ome
- quinolincarbonitrilos
- mielogen
- anilino
- leukemia
- Prior art date
Links
- 230000001684 chronic effect Effects 0.000 title 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title 1
- 208000032839 leukemia Diseases 0.000 title 1
- 108010032806 molgramostim Proteins 0.000 title 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1.- Una composición farmacéutica caracterizada porque comprende una cantidad inhibidora de CML de un compuesto que tiene la estructura de la fórmula I:en donde n es un entero de 0-3;X es N, CH;R es alquilo de 1 a 3 átomos de carbono;R1 es 2,4-diCI, 5-Ome en posición para, orto o meta; 2,4-diCI; 3,4,5-tri-OMe; 2-CI, 5-OMe; 2-Me, 5-OMe; 2,4-di-Me; 2,4-diMe-5-OMe, 2,4-diCI, 5-OEt; y R2 es alquilo de 1 a 3 átomos de carbono y sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51781903P | 2003-11-06 | 2003-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5690608A2 true CO5690608A2 (es) | 2006-10-31 |
Family
ID=34590192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06051033A CO5690608A2 (es) | 2003-11-06 | 2006-05-26 | 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7417148B2 (es) |
| EP (1) | EP1680119A1 (es) |
| JP (1) | JP2007533655A (es) |
| KR (1) | KR20060118461A (es) |
| CN (1) | CN1874776A (es) |
| AU (1) | AU2004289243B2 (es) |
| BR (1) | BRPI0416289A (es) |
| CA (1) | CA2543163A1 (es) |
| CO (1) | CO5690608A2 (es) |
| CR (1) | CR8350A (es) |
| EC (1) | ECSP066548A (es) |
| IL (1) | IL175424A0 (es) |
| MX (1) | MXPA06004744A (es) |
| NO (1) | NO20062255L (es) |
| RU (1) | RU2006113691A (es) |
| SG (1) | SG146681A1 (es) |
| WO (1) | WO2005046693A1 (es) |
| ZA (1) | ZA200603596B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004289243B2 (en) * | 2003-11-06 | 2010-07-22 | Wyeth Llc | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
| JP5121706B2 (ja) * | 2005-06-17 | 2013-01-16 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | Ｓｒｃキナーゼ阻害薬による溶骨性病変の阻害 |
| BRPI0611977A2 (pt) * | 2005-06-24 | 2010-10-13 | Wyeth Corp | uso de um composto |
| US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
| WO2008064004A2 (en) * | 2006-11-16 | 2008-05-29 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
| WO2008060283A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
| CA2868899C (en) * | 2007-06-01 | 2017-06-13 | Wyeth Llc | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene |
| WO2013187967A1 (en) | 2012-06-15 | 2013-12-19 | Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") | Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control |
| BR112014032346A2 (pt) | 2012-06-26 | 2017-06-27 | Del Mar Pharmaceuticals | métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes |
| US9776970B2 (en) | 2014-02-20 | 2017-10-03 | Apotex Inc. | Bosutinib forms and preparation methods thereof |
| SG11201705767PA (en) | 2015-01-13 | 2017-08-30 | Univ Kyoto | Agent for preventing and/or treating amyotrophic lateral sclerosis |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US12398355B2 (en) | 2019-04-09 | 2025-08-26 | Massachusetts Institute Of Technology | Micro physiological model for neuronal and muscular diseases and disorders |
| WO2022053130A1 (en) | 2020-09-09 | 2022-03-17 | Sid Alex Group, S.R.O. | Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| TWI275390B (en) * | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US20040229880A1 (en) | 2003-02-21 | 2004-11-18 | Wyeth | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury |
| AU2004289243B2 (en) * | 2003-11-06 | 2010-07-22 | Wyeth Llc | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
-
2004
- 2004-11-03 AU AU2004289243A patent/AU2004289243B2/en not_active Expired
- 2004-11-03 EP EP04800721A patent/EP1680119A1/en not_active Withdrawn
- 2004-11-03 MX MXPA06004744A patent/MXPA06004744A/es active IP Right Grant
- 2004-11-03 SG SG200807148-2A patent/SG146681A1/en unknown
- 2004-11-03 WO PCT/US2004/036722 patent/WO2005046693A1/en not_active Ceased
- 2004-11-03 US US10/980,097 patent/US7417148B2/en active Active
- 2004-11-03 JP JP2006539641A patent/JP2007533655A/ja active Pending
- 2004-11-03 RU RU2006113691/14A patent/RU2006113691A/ru unknown
- 2004-11-03 KR KR1020067008812A patent/KR20060118461A/ko not_active Withdrawn
- 2004-11-03 CN CNA2004800323110A patent/CN1874776A/zh active Pending
- 2004-11-03 CA CA002543163A patent/CA2543163A1/en not_active Abandoned
- 2004-11-03 BR BRPI0416289-7A patent/BRPI0416289A/pt not_active Application Discontinuation
-
2006
- 2006-04-20 CR CR8350A patent/CR8350A/es not_active Application Discontinuation
- 2006-05-04 IL IL175424A patent/IL175424A0/en unknown
- 2006-05-05 EC EC2006006548A patent/ECSP066548A/es unknown
- 2006-05-05 ZA ZA200603596A patent/ZA200603596B/xx unknown
- 2006-05-19 NO NO20062255A patent/NO20062255L/no not_active Application Discontinuation
- 2006-05-26 CO CO06051033A patent/CO5690608A2/es not_active Application Discontinuation
-
2008
- 2008-06-16 US US12/139,834 patent/US7919625B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20100029677A1 (en) | 2010-02-04 |
| ZA200603596B (en) | 2009-12-30 |
| AU2004289243B2 (en) | 2010-07-22 |
| NO20062255L (no) | 2006-08-01 |
| MXPA06004744A (es) | 2006-07-05 |
| RU2006113691A (ru) | 2007-12-20 |
| CR8350A (es) | 2006-10-06 |
| US20050101780A1 (en) | 2005-05-12 |
| WO2005046693A1 (en) | 2005-05-26 |
| ECSP066548A (es) | 2006-10-17 |
| AU2004289243A1 (en) | 2005-05-26 |
| CN1874776A (zh) | 2006-12-06 |
| JP2007533655A (ja) | 2007-11-22 |
| IL175424A0 (en) | 2008-04-13 |
| CA2543163A1 (en) | 2005-05-26 |
| SG146681A1 (en) | 2008-10-30 |
| KR20060118461A (ko) | 2006-11-23 |
| BRPI0416289A (pt) | 2007-01-23 |
| EP1680119A1 (en) | 2006-07-19 |
| US7417148B2 (en) | 2008-08-26 |
| US7919625B2 (en) | 2011-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5690608A2 (es) | 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica | |
| PA8545301A1 (es) | Nuevos derivados de quinolina | |
| AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
| AR077415A2 (es) | Derivados de oxindol sustituido , medicamentos que los comprenden y uso de los mismos | |
| ES2543607T3 (es) | Ciertas amidas sustituidas, método de obtención, y método de su uso | |
| CO6321254A2 (es) | Pirimidin -5-carboxamidas sustituidas 281 | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| TW200641539A (en) | Salt suitable for an acid generator and a chemically amplified resist composition containing the same | |
| UY28014A1 (es) | Compuestos quimicos | |
| AR029773A1 (es) | Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados y una composicion de un monomero etilenicamente insaturado preparada con el mismo | |
| AR043929A1 (es) | Fases cristalinas de un inhibidor del hcv | |
| WO2007099162A3 (fr) | Derive de resveratrol a longue chaine hydroxylee utiles comme neurotrophiques | |
| TW200728915A (en) | A salt suitable for an acid generator and a chemically amplified resist composition containing the same | |
| BRPI0409105A (pt) | análogos de quinobenzoxazina substituìdos | |
| MX2024007242A (es) | Lipido y composicion utilizada para la administracion. | |
| CO5700776A2 (es) | Compuestos utiles para el tratamiento de enfermedades | |
| PA8531701A1 (es) | Derivados de pirimidina | |
| UY27979A1 (es) | Indoles sustituidos en posición 2,4 | |
| ECSP055972A (es) | 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas | |
| UY27610A1 (es) | Combinación de inhibidores de ptm o inhibidores de la secreción de apob con fibratos para la utilización como medicamentos | |
| AR044175A1 (es) | Compuestos de cefemo | |
| AR035601A1 (es) | Procesos de preparacion de inhibidores del intercambiador de sodio-hidrogeno de tipo 1, inhibidores, sales de dichos compuestos, composiciones farmaceuticas y uso de los mismos en la preparación de medicamentos | |
| CO5170535A1 (es) | Derivados de n-[2-(4-aminofenil)etil]2,3-dihidro-1,4- benzodioxin-2-metanamina, su preparacion y su aplciacion en terapeutica | |
| AR057464A1 (es) | Procedimiento para la preparacion de derivados de sulfonamida | |
| AR048582A1 (es) | Metodos para tratar esclerosis multiple y composiciones farmaceuticas para ese fin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |